Partnerships

Inventiva in Numbers

2

Partnerships (Abbvie and Boehringer Ingelheim)

3

Innovative Clinical Programmes

90

People in our Scientific Team

13

Patent Families

A Library of

240,000

Compounds

Welcome to Inventiva Pharma

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Share Information

Therapeutic Areas

Systemic sclerosis
(SSc)

Systemic sclerosis is a rare and severe autoimmune disease with a prevalence of approximately 154 per million in each of the United States and Europe.

Inventiva is developing lanifibranor, a small molecule that has been shown in preclinical studies to reduce fibrosis in the organs affected by SSc: the skin, lungs and kidneys with positive effects on lung and heart function.

We are currently investigating lanifibranor for the treatment of diffuse cutaneous SSc in FASSTfor the treatment of diffuse cutaneous SSc, a Phase 2b clinical trial, with results expected in Q1 2019.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.